DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
2005 Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, Jf; Hoctin Boes, G; Houghton, J; Locker, Gy; Tobias, Js; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer.
2014 Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G.
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
2011 Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
2011 Giuliano, Mario; Giordano, A; Jackson, S; Hess, Kr; De Giorgi, U; Mego, M; Handy, Bc; Ueno, Nt; Alvarez, Rh; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Valero, V; Hortobagyi, Gn; Reuben, Jm; Cristofanilli, M.
Prognostic factors: rationale and methods of analysis and integration.
1994 G. M., Clark; S. G., Hilsenbeck; P. M., Ravdin; DE LAURENTIIS, Michelino; C. K., Osborne
External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life.
2003 DI LORENZO, G; Autorino, R; Ciardiello, F; Raben, D; Bianco, C; Troiani, T; Pizza, C; DE LAURENTIIS, Michelino; Pensabene, M; D., ARMIENTO M; Bianco, Ar; DE PLACIDO, Sabino
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study.
1997 Fontanini, G.; Lucchi, M.; Vignati, S.; Mussi, A.; Ciardiello, F.; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Survival, quality of life and breast cancer.
2001 Mosconi, P; Colozza, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Maltoni, M.
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
2003 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, Chiara; C., Gallo; F., Perrone; Pepe, Stefano; A., Ruggiero; Marinelli, Alfredo; Pagliarulo, Clorindo; Pettinato, Guido; G., Petrella; Bianco, ANGELO RAFFAELE
Survival analysis of censored data: neural network analysis detection of complex interactions between variables.
1994 DE LAURENTIIS, Michelino; P. M., Ravdin
A technique for using neural network analysis to perform survival analysis of censored data.
1994 DE LAURENTIIS, Michelino; P. M., Ravdin
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases.
1996 Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer.
1995 Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues.
1996 Panico, L.; D'Antonio, A.; Salvatore, G.; Mazza, E.; Tortora, Giampaolo; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Giordano, T.; Merino, M.; Salomon, D. S.; Gullick, W. J.; Pettinato, Guido; Bianco, A. R.; Ciardiello, F.
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
2006 Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R.
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
2007 DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | 1.1 Articolo in rivista | 2005 | Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, Jf; Hoctin Boes, G; Houghton, J; Locker, Gy; Tobias, Js; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara | |
| High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. | 1.1 Articolo in rivista | 2014 | Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G. | |
| Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. | 1.1 Articolo in rivista | 2011 | Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm | |
| Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. | 1.1 Articolo in rivista | 2011 | Giuliano, Mario; Giordano, A; Jackson, S; Hess, Kr; De Giorgi, U; Mego, M; Handy, Bc; Ueno, Nt; Alvarez, Rh; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Valero, V; Hortobagyi, Gn; Reuben, Jm; Cristofanilli, M. | |
| Prognostic factors: rationale and methods of analysis and integration. | 1.1 Articolo in rivista | 1994 | G. M., Clark; S. G., Hilsenbeck; P. M., Ravdin; DE LAURENTIIS, Michelino; C. K., Osborne | |
| External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; Ciardiello, F; Raben, D; Bianco, C; Troiani, T; Pizza, C; DE LAURENTIIS, Michelino; Pensabene, M; D., ARMIENTO M; Bianco, Ar; DE PLACIDO, Sabino | |
| Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. | 1.1 Articolo in rivista | 1997 | Fontanini, G.; Lucchi, M.; Vignati, S.; Mussi, A.; Ciardiello, F.; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Survival, quality of life and breast cancer. | 1.1 Articolo in rivista | 2001 | Mosconi, P; Colozza, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Maltoni, M. | |
| Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. | 1.1 Articolo in rivista | 2003 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, Chiara; C., Gallo; F., Perrone; Pepe, Stefano; A., Ruggiero; Marinelli, Alfredo; Pagliarulo, Clorindo; Pettinato, Guido; G., Petrella; Bianco, ANGELO RAFFAELE | |
| Survival analysis of censored data: neural network analysis detection of complex interactions between variables. | 1.1 Articolo in rivista | 1994 | DE LAURENTIIS, Michelino; P. M., Ravdin | |
| A technique for using neural network analysis to perform survival analysis of censored data. | 1.1 Articolo in rivista | 1994 | DE LAURENTIIS, Michelino; P. M., Ravdin | |
| Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. | 1.1 Articolo in rivista | 1996 | Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino | |
| Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. | 1.1 Articolo in rivista | 1995 | Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues. | 1.1 Articolo in rivista | 1996 | Panico, L.; D'Antonio, A.; Salvatore, G.; Mazza, E.; Tortora, Giampaolo; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Giordano, T.; Merino, M.; Salomon, D. S.; Gullick, W. J.; Pettinato, Guido; Bianco, A. R.; Ciardiello, F. | |
| Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. | 1.1 Articolo in rivista | 2006 | Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R. | |
| Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. | 1.1 Articolo in rivista | 2007 | DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino |